Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases
Out of numerous studied monoclonal antibodies, only a few reached the stage of clinical application. The CD20 molecule, non-glycolysed phospholipoprotein (usually termed B1), belonging to the tetraspan (TM4SF) family, 35-37 kD, is characteristic for all mature B lymphocytes, including CLL cells. The...
Main Authors: | Pejčić Ivica, Vrbić Svetislav |
---|---|
Format: | Article |
Language: | English |
Published: |
Institute of Oncology, Sremska Kamenica, Serbia
2009-01-01
|
Series: | Archive of Oncology |
Subjects: | |
Online Access: | http://www.doiserbia.nb.rs/img/doi/0354-7310/2009/0354-73100904065P.pdf |
Similar Items
-
Utility of CD200 expression and CD20 antibody binding capacity in differentiating chronic lymphocytic leukemia from other chronic lymphoproliferative disorders
by: R Poongodi, et al.
Published: (2018-01-01) -
Production and Characterization of New Anti-Human CD20 Monoclonal Antibody
by: Mahdi Fasihi-Ramandi, et al.
Published: (2015-10-01) -
Anti-CD20 monoclonal antibodies: reviewing a revolution
by: J. M. L. Casan, et al.
Published: (2018-12-01) -
Radiolabeling and biodistribution of monoclonal antibody (MAb) anti-CD20 with iodine-131
by: Akinkunmi Ganiyu Akanji, et al.
Published: (2005-10-01) -
Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contra
by: K. A. Sychevskaya, et al.
Published: (2022-04-01)